German chemical company BASF and French start up Poietis have signed a research and development agreement on 3D bioprinting technology for advanced skin care applications.
BASF aims to improve its skin equivalent model Mimeskin by using Poietis’ innovative 3D bioprinting technology. Founded in 2014, Poietis has developed a “4D laser-assisted bioprinting” method that provides an extremely high resolution at a printing speed of 10,000 drops per second.
Dr. Fabien Guillemot, Founder and President of Poietis, states: “We are extremely pleased about this collaboration. Having long-term expertise in solutions for the dermocosmetics market, BASF understands the benefits of 3D laser-assisted bioprinting compared to conventional cell culture technologies and other bioprinting methods. The partnership also emphasizes bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy.”
Dr. Sebastien Cadau, responsible for tissue engineering development at BASF, explains: “Compared to other bioprinting methods the laser-assisted technology provides higher resolution when it comes to the patterning of cells. The partnership with Poietis allows BASF to secure its strategic advantage in better understanding the skin mechanisms which support the development and testing of advanced cosmetic bioactives for skin care applications.”
A similar agreement has been signed by 3D bioprinting company Organovo and L’Oreal, who teamed up to 3D print skin tissue models for cosmetical testing.